Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7
Primary Industries
- Drugs
- Therapeutic
- Biotechnology
- Pharmaceuticals
- Diagnostic
- Disease
- Wound Care
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 2496
License Grant
Pursuant to the research agreement, the Company has exclusive rights to patent applications filed in the United States and in Europe disclosing the use of Thymosin beta 4 for the treatment of septic shock and associated syndromes including ARDS. Two U.S. patents have issued with the University.
License Property
The first patent, No. 5,578,570, entitled Method of Treating Septic Shock Using Thymosin beta 4, issued November 26, 1996; the second patent, No. 5,593,964, entitled Method of Treating Septic Shock By Preventing Actin Polymerization, issued on January 14, 1997. Thymosin beta 4 is a chemically synthesized copy of a natural human peptide, consisting of 43 amino acid residues. Thymosin beta 4 is found in high concentration in blood platelets, white blood cells and in a majority of other tissues, and has been shown to be a unique peptide with well-characterized biochemical properties and actions. Thymosin beta 4 is believed to be involved in a wide variety of cellular and physiological processes as shown by the enhancement of antigen presentation by macrophages in mice, macrophage migration inhibition in guinea pigs and phenotypic changes in T-cell lines. In animal models of septic shock, Thymosin beta 4 has been shown to reduce death in a dose-dependent manner, presumably by modulating pathologic mediators of inflammation and cell death. (2003).
Field of Use
Licensee is a pharmaceutical research and development company focusing on the development of products to treat a variety of human diseases. To date, the Company has conducted limited pharmacology and toxicology testing in animals. Additional animal testing will be required before Thymosin beta 4 can be tested in humans.
IPSCIO Record ID: 26491
License Grant
The Licensor licenses the U.S. patent rights to the Licensee on a sole and exclusive basis. A United States composition of matter patent for Thymosin beta 4.
Pursuant to the research agreement, the Licensee has exclusive rights to patent applications filed in the United States and in Europe disclosing the use of Thymosin beta 4 for the treatment of septic shock and associated syndromes including ARDS.
License Property
Two U.S. patents have issued. The first patent, No. 5,578,570, entitled Method of Treating Septic Shock Using Thymosin beta 4, issued November 26, 1996; the second patent, No. 5,593,964, entitled Method of Treating Septic Shock By Preventing Actin Polymerization, issued on January 14, 1997.
Thymosin beta 4 is a chemically synthesized copy of a natural human peptide, consisting of 43 amino acid residues. Thymosin beta 4 is found in high concentration in blood platelets, white blood cells and in a majority of other tissues, and has been shown to be a unique peptide with well-characterized biochemical properties and actions. Thymosin beta 4 is believed to be involved in a wide variety of cellular and physiological processes as shown by the enhancement of antigen presentation by macrophages in mice, macrophage migration inhibition in guinea pigs and phenotypic changes in T-cell lines. In animal models of septic shock, Thymosin beta 4 has been shown to reduce death in a dose-dependent manner, presumably by modulating pathologic mediators of inflammation and cell death.
Field of Use
Licensee is a pharmaceutical research and development company focusing on the development of products to treat a variety of human diseases.
IPSCIO Record ID: 26739
License Grant
Under a research agreement with the University, the Licensee funded T(beta)4 research for the Licensor and was granted a sole and exclusive world-wide license to any patents that resulted from such research.
License Property
T(beta)4 is used for the treatment of septic shock and associated syndromes, including ARDS.
Two U.S. patents have issued. The first patent, No. 5,578,570, entitled Method of Treating Septic Shock Using T(beta)4 and the second patent, No. 5,593,964, entitled Method of Treating Septic Shock By Preventing Actin Polymerization. The Company’s current primary business focus is the commercialization of Thymosin beta 4, a 43 amino acid peptide (T(beta)4).
Field of Use
The Licensee is concentrating its efforts on the use of T(beta)4 for the treatment of injured tissue and non-healing wounds to enable more rapid repair and/or tissue regeneration.
IPSCIO Record ID: 1625
License Grant
In August 1994, the Company entered into a license agreement (the New License Agreement) which superseded the original license agreement (the Original License Agreement) between the parties entered into in 1990. Under the agreement, the Company granted an exclusive license to the Company’s patent and other proprietary rights with respect to Thymosin alpha 1 to develop, test, make, use and sell Thymosin alpha 1 and products containing Thymosin alpha 1 for all human and animal therapeutic and diagnostic uses.
Field of Use
The Company's first commercial development project focused on a 28 amino acid peptide, called Thymosin alpha 1, shown to regulate the immune system in animal models.
IPSCIO Record ID: 204342
License Grant
Licensor grants to Licensee an exclusive license under Licensor Patent Rights and Know-How to make, have made, use, offer to sell, sell and import Product(s) in the Territory for use in the Field.
License Property
The Lead Product shall mean a Product for only one Major Indication that is the first Product for the first Major Indication as to which a Phase III Clinical Trial is initiated. The patents and know how relate to Antagonists of HMG-1 for Treating Inflammatory Conditions.
High-mobility group box 1 protein (HMGB1), a chromatin associated nuclear protein and extracellular damage associated molecular pattern molecule (DAMP), is an evolutionarily ancient and critical regulator of cell death and survival.
Field of Use
The Field shall mean the Development and Commercialization of Products for the treatment or prevention or amelioration of a disease, disorder or medical condition in humans or non-human animals. For purposes of clarity, Field shall not include the Development or Commercialization of products for the diagnosis of any disease, disorder or medical condition in humans or non-human animals.
IPSCIO Record ID: 203522
License Grant
For the License to Finished Products, Licensor grants the Licensee of Portugal, only in the Territory, the sole and exclusive, transferable, sub-licensable right in the Field of Use under the Know-How, the Documentation, the Licensor Improvements, Joint Improvements and the Patents
– to use Bulk Active Material to produce or have produced Finished Products only for making Sales in the Field of Use, either directly, through its Affiliates or through Distributors or Sub-Licensees, in the Territory; – and, to use Bulk Active Material to conduct internal research and development activities relative to and for the benefit of making Joint Improvements or Licensee Improvements to Finished Products.
For the License to Trademark for the Bulk Active Material, Licensor grants, only in the Territory, to Licensee a non-exclusive, transferable, sub-licensable right in the Field of Use to use, copy, publish, display, distribute and disseminate, on or in any tangible form or electronic media, the Trademark for the Bulk Active Material only in connection with the Sale of Finished Products in the Field of Use and associated marketing collaterals and packaging in accordance with the Trademark Style Guide and Requirements.
License Property
Thymosin beta 4 (TB4) is a novel drug undergoing human clinical trials for chronic wounds.
TB4 is a naturally occurring 43-amino acid peptide present in virtually all human cells. TB4 represents a new class of wound healing drug and is different from other wound repair factors, such as growth factors, in that it promotes endothelial cell differentiation and keratinocyte cell migration, down-regulates a number of inflammatory cytokines and chemokines, and has a very low molecular weight, allowing it to diffuse relatively long distances through tissues. A key mechanism of action is TB4's ability to regulate the cell-building protein, actin, a vital component of the cytoskeleton. It has been the subject of a significant amount of research at the NIH and a number of other academic institutions, and has been reported to be effective in the repair of dermal and corneal wounds in numerous animal models under a variety of conditions.
Patents are for Methods of treating Epidennolysis Bullosa and Other similar Dermatological Indications with Thymosin Beta 4, Analogues, isoforms and Other Derivatives, Treatment of Infections and Other Disorders, Thymosin B4 Promotes Wound Repair, Methods of Treating and Preventing Anthrax Induced Pathologies with Thymosin Beta 4 Analogs, isoforms and Other Derivatives incorporated into 2600-108, Methods of Healing or Preventing Inflammation, Damage and Other Changes that Occur prior to, During or Immediately after a Myocardial Event with Thymosin Beta 4, Analogues, isoforms, and other Derivatives, Methods of Healing, Treating and/ or Reversal of Stenosis or ·Restenosis of the Myocardium and Coronary Vessels, Heart Valves and Septa Injuries or Defects Using Thymosin Beta 4, or TB4 Analogues, isoforms, Antibodies or anti-sense Peptides, and, Methods of Treating and Preventing Physical, Cognitive and Biological Damage Due to Ionizing Radiation Exposure by Administering LKKTET Peptides, TB4, analogues, isoforms and Other Derivatives.
Finished Product means any prescription or over-the-counter pharmaceutical product, or a medical device, in the Field of Use containing the Bulk Active Material.
The trademark will be determined by Licensee and approved by Licensor.
Field of Use
The field of use means the availability and use of the Finished Products formulated for the prevention and/or treatment of any indication for external wounds and internal wounds. For the sake of clarity, such indications shall include, but not be limited to, the gastrointestinal tract and burns; and shall not include ocular wounds. It is understood that any treatment or use of the Finished Products may not be incorporated into the form of any type of cosmetic product.
IPSCIO Record ID: 2505
License Grant
The Company entered into the Alpha Rights Acquisition Agreement to sell its rights to receive from Licensee royalties on the future sales of Thymosin alpha 1. Thymosin alpha 1 (T(alpha)1) is a 28 amino acid peptide now approved for the treatment of hepatitis B and C and as an immune adjuvant outside the United States.
Field of Use
Under the license, the Licensee had the right to develop, test, make, use and sell Thymosin alpha 1 and products containing Thymosin alpha 1 for all human and animal therapeutic and diagnostic uses.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
